CD274 and non-small cell lung carcinoma: Additionally, patients exhibited greater efficacy and had significantly fewer adverse effects (10% vs 54%) on nivolumab. Mutations in STK11 confer resistance to PD-L1 therapy and are often associated with co-mutations in KRAS, making the selection of treatment for STK11 mutated NSCLC a significant challenge [54,55].